Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne MedicinesONC -0.88%81 Equity-to-Asset is 0.56 as of Jun. 2026, which is 18% below its 10-year median of 0.68. GuruFocus rates ONC with a GF Score™ of 81/100 and a GF Value™ of $377.45 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,415 Biotechnology companies, BeOne Medicines ranks worse than 61.91% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BeOne Medicines's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $5,174 Mil. BeOne Medicines's Total Assets for the quarter that ended in Jun. 2026 was $9,176 Mil.
Therefore, BeOne Medicines's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.56.
The historical rank and industry rank for BeOne Medicines's Equity-to-Asset or its related term are showing as below:
ONC'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53 Med: 0.68 Max: 0.87
Current: 0.56
During the past 13 years, the highest Equity to Asset Ratio of BeOne Medicines was 0.87. The lowest was 0.53. And the median was 0.68.
ONC's Equity-to-Asset is ranked worse than 61.91% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs ONC: 0.56
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BeOne Medicines Equity-to-Asset Related Terms
BeOne Medicines Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONC vs ALNY, RVMD, RPRX: Equity-to-Asset Comparison
For the Biotechnology subindustry, BeOne Medicines's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BeOne Medicines's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (ONC) has a Equity-to-Asset of 0.56 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BeOne Medicines and its competitors. This is 18% below median its historical median of 0.68. Over the past decade, BeOne Medicines' Equity-to-Asset has ranged from 0.53 to 0.87. According to the industry distribution chart, BeOne Medicines ranks #876 out of 1415 companies in the Biotechnology industry, placing it in the top 61.9%.
Is BeOne Medicines' Equity-to-Asset too high?
BeOne Medicines' current Equity-to-Asset of 0.56 is 18% below median its 10-year median of 0.68. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 0.87. The Biotechnology industry median Equity-to-Asset is 0.68. BeOne Medicines' value of 0.56 is 17.6% below this industry median. Based on the distribution chart, BeOne Medicines ranks #876 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Equity-to-Asset compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #876 out of 1415 companies for Equity-to-Asset. This places BeOne Medicines in the lower half of its industry. The industry median Equity-to-Asset is 0.68. BeOne Medicines' value of 0.56 is 17.6% below this benchmark. Historically, BeOne Medicines' own Equity-to-Asset has ranged from 0.53 to 0.87 over the past decade. While the company's 10-year median is 0.68 vs. the industry median of 0.68, BeOne Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Equity-to-Asset of 0.56 is 17.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Equity-to-Asset is 0.56, which is 18% below median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $377.45, compared to a current price of $372.49 — trading 1.3% below its estimated fair value. The current Equity-to-Asset is 0.56, which is 18% below median its 10-year median of 0.68 and 17.6% below the Biotechnology industry median of 0.68. BeOne Medicines' overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Equity-to-Asset is 0.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $372.49 is trading 1.3% below its estimated GF Value™ of $377.45.
GuruFocus considers BeOne Medicines to be Fairly Valued.
Key valuation signals for ONC:
Equity-to-Asset: 0.56 (18% below median its 10-year median of 0.68)
GF Value™: $377.45 vs. price of $372.49 (1.3% below fair value)
Industry Position: 17.6% below the Biotechnology median (#876 of 1415)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for ONC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
